Stevanato Group S.p.A. (STVN)

Market Cap	5.97B
Revenue (ttm)	1.14B
Net Income (ttm)	121.94M
Shares Out	272.90M
EPS (ttm)	0.45
PE Ratio	49.10
Forward PE	37.53
Dividend	$0.06 (0.27%)
Ex-Dividend Date	Jun 4, 2024

Volume	349,240
Open	21.29
Previous Close	22.08
Day's Range	20.95 - 22.03
52-Week Range	16.56 - 29.68
Beta	0.52
Analysts	Buy
Price Target	25.08 (+13.85%)
Earnings Date	May 8, 2025

About STVN

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injector...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Jul 16, 2021
• Employees: 5,521
• Stock Exchange: NYSE
• Ticker Symbol: STVN
• Website: https://www.stevanatogroup.com

Financial Performance

In 2024, Stevanato Group's revenue was 1.10 billion, an increase of 1.72% compared to the previous year's 1.09 billion. Earnings were 117.78 million, a decrease of -19.13%.

Financial numbers in EUR

Analyst Forecast

According to 6 analysts, the average rating for STVN stock is "Buy." The 12-month stock price forecast is $25.08, which is an increase of 13.85% from the latest price.

Price Target

$25.08

(13.85% upside)

Analyst Consensus: Buy